BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Negro F. Natural history of NASH and HCC. Liver Int 2020;40:72-76. [DOI: 10.1111/liv.14362] [Cited by in Crossref: 63] [Cited by in F6Publishing: 60] [Article Influence: 21.0] [Reference Citation Analysis]
Number Citing Articles
1 Hinkson A, Lally H, Gibson H, Jones R, Rowe IA, Shinkins B, Parker R. Meta-analysis: Enhanced liver fibrosis test to identify hepatic fibrosis in chronic liver diseases. Aliment Pharmacol Ther 2023. [PMID: 36650720 DOI: 10.1111/apt.17385] [Reference Citation Analysis]
2 Akl MG, Widenmaier SB. Immunometabolic factors contributing to obesity-linked hepatocellular carcinoma. Front Cell Dev Biol 2023;10. [DOI: 10.3389/fcell.2022.1089124] [Reference Citation Analysis]
3 Ho SY, Yuan MH, Liu PH, Hsu CY, Huang YH, Liao JI, Su CW, Wang CL, Hou MC, Huo TI. Cryptogenic hepatocellular carcinoma: characteristics, outcome, and prognostic role of albumin-bilirubin (ALBI) grade vs easy ALBI grade. Scand J Gastroenterol 2023;58:61-9. [PMID: 35830511 DOI: 10.1080/00365521.2022.2098052] [Reference Citation Analysis]
4 Mouhoubi N, Bamba-Funck J, Sutton A, Blaise L, Seror O, Ganne-Carrié N, Ziol M, N'Kontchou G, Charnaux N, Nahon P, Nault JC, Guyot E. Sulfatase 2 Along with Syndecan 1 and Glypican 3 Serum Levels are Associated with a Prognostic Value in Patients with Alcoholic Cirrhosis-Related Advanced Hepatocellular Carcinoma. J Hepatocell Carcinoma 2022;9:1369-83. [PMID: 36597436 DOI: 10.2147/JHC.S382226] [Reference Citation Analysis]
5 Ahmed EA, El-Derany MO, Anwar AM, Saied EM, Magdeldin S. Metabolomics and Lipidomics Screening Reveal Reprogrammed Signaling Pathways toward Cancer Development in Non-Alcoholic Steatohepatitis. Int J Mol Sci 2022;24. [PMID: 36613653 DOI: 10.3390/ijms24010210] [Reference Citation Analysis]
6 Antwi SO, Craver EC, Nartey YA, Sartorius K, Patel T. Metabolic Risk Factors for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: A Prospective Study. Cancers (Basel) 2022;14. [PMID: 36551719 DOI: 10.3390/cancers14246234] [Reference Citation Analysis]
7 Cavalcante LN, Dezan MGF, Paz CLDSL, Lyra AC. RISK FACTORS FOR HEPATOCELLULAR CARCINOMA IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE. Arq Gastroenterol 2022. [DOI: 10.1590/s0004-2803.202204000-93] [Reference Citation Analysis]
8 Sommerauer C, Kutter C. Noncoding RNAs in liver physiology and metabolic diseases. Am J Physiol Cell Physiol 2022. [PMID: 35968891 DOI: 10.1152/ajpcell.00232.2022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Sydor S, Dandyk C, Schwerdt J, Manka P, Benndorf D, Lehmann T, Schallert K, Wolf M, Reichl U, Canbay A, Bechmann LP, Heyer R. Discovering Biomarkers for Non-Alcoholic Steatohepatitis Patients with and without Hepatocellular Carcinoma Using Fecal Metaproteomics. IJMS 2022;23:8841. [DOI: 10.3390/ijms23168841] [Reference Citation Analysis]
10 Hany NM, Eissa S, Basyouni M, Hasanin AH, Aboul-Ela YM, Elmagd NMA, Montasser IF, Ali MA, Skipp PJ, Matboli M. Modulation of hepatic stellate cells by Mutaflor® probiotic in non-alcoholic fatty liver disease management. J Transl Med 2022;20:342. [PMID: 35907883 DOI: 10.1186/s12967-022-03543-z] [Reference Citation Analysis]
11 Bacil GP, Cogliati B, Cardoso DR, Barbisan LF, Romualdo GR. Are isothiocyanates and polyphenols from Brassicaceae vegetables emerging as preventive/therapeutic strategies for NAFLD? The landscape of recent preclinical findings. Food Funct 2022. [PMID: 35899794 DOI: 10.1039/d2fo01488b] [Reference Citation Analysis]
12 Menshikov KV, Sultanbaev AV, Musin SI, Rakhmatullina IR, Menshikova IA, Abdeev RR, Sultanbaeva NI, Popova EV, Serebrennikov GA. Hepatocellular Carcinoma: Aetiology and Mechanisms of Development. A Literature Review. Kreativnaâ hirurgiâ i onkologiâ 2022;12:139-150. [DOI: 10.24060/2076-3093-2022-12-2-139-150] [Reference Citation Analysis]
13 Tong X, Xu S, Zhai D. Multiple Mechanisms of Shenqi Pill in Treating Nonalcoholic Fatty Liver Disease Based on Network Pharmacology and Molecular Docking. Evid Based Complement Alternat Med 2022;2022:2384140. [PMID: 35795275 DOI: 10.1155/2022/2384140] [Reference Citation Analysis]
14 Adetutu Adisa R, Adegboyega Sulaimon L. Hepatocellular Carcinoma. Hepatotoxicity [Working Title] 2022. [DOI: 10.5772/intechopen.105473] [Reference Citation Analysis]
15 Saha M, Manna K, Das Saha K. Melatonin Suppresses NLRP3 Inflammasome Activation via TLR4/NF-κB and P2X7R Signaling in High-Fat Diet-Induced Murine NASH Model. J Inflamm Res 2022;15:3235-58. [PMID: 35668917 DOI: 10.2147/JIR.S343236] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
16 Bashir A, Duseja A, De A, Mehta M, Tiwari P. Non-alcoholic fatty liver disease development: A multifactorial pathogenic phenomena. Liver Research 2022. [DOI: 10.1016/j.livres.2022.05.002] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
17 Hosseini-Fard SR, Dehpour AR, Emamgholipour S, Golestani A. Naltrexone protects against BDL-induced cirrhosis in Wistar rats by attenuating thrombospondin-1 and enhancing antioxidant defense system via Nrf-2. Life Sci 2022;300:120576. [PMID: 35487305 DOI: 10.1016/j.lfs.2022.120576] [Reference Citation Analysis]
18 Yao M, Yang JL, Wang DF, Wang L, Chen Y, Yao DF. Encouraging specific biomarkers-based therapeutic strategies for hepatocellular carcinoma. World J Clin Cases 2022; 10(11): 3321-3333 [DOI: 10.12998/wjcc.v10.i11.3321] [Reference Citation Analysis]
19 Selvaggi F, Catalano T, Cotellese R, Aceto GM. Targeting Wnt/β-Catenin Pathways in Primary Liver Tumours: From Microenvironment Signaling to Therapeutic Agents. Cancers 2022;14:1912. [DOI: 10.3390/cancers14081912] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Fang X, Wang H, Tan X, Ye T, Xu Y, Fan J. Elevated Serum Regulator of Calcineurin 2 is Associated With an Increased Risk of Non-Alcoholic Fatty Liver Disease. Front Pharmacol 2022;13:840764. [PMID: 35370729 DOI: 10.3389/fphar.2022.840764] [Reference Citation Analysis]
21 Aggarwal P, Noureddin M, Harrison S, Jeannin S, Alkhouri N. Nonalcoholic steatohepatitis (NASH) cirrhosis: A snapshot of therapeutic agents in clinical development and the optimal design for clinical trials. Expert Opinion on Investigational Drugs. [DOI: 10.1080/13543784.2022.2032640] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Jarvis H, O'Keefe H, Craig D, Stow D, Hanratty B, Anstee QM. Does moderate alcohol consumption accelerate the progression of liver disease in NAFLD? A systematic review and narrative synthesis. BMJ Open 2022;12:e049767. [PMID: 34983755 DOI: 10.1136/bmjopen-2021-049767] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Bedi S, Davis A, Navarro V. Reducing the Risk of and Screening for Liver Cancer. Hepato-Pancreato-Biliary Malignancies 2022. [DOI: 10.1007/978-3-030-41683-6_12] [Reference Citation Analysis]
24 Thamby B, Sheeja S. Impact of Data Mining on HCC Prediction: Survey. ICT Analysis and Applications 2022. [DOI: 10.1007/978-981-16-5655-2_75] [Reference Citation Analysis]
25 Hakami A, Elmakki E. Nonalcoholic steatohepatitis-induced hepatocellular carcinoma. King Khalid Univ J Health Sci 2022;7:1. [DOI: 10.4103/kkujhs.kkujhs_1_22] [Reference Citation Analysis]
26 Hidalgo I, Fonseca-coronado S, Ceballos G, Meaney E, Nájera N. Dislipidemias, hígado graso y enfermedad cardiovascular. Cardiovasc Metab Sci 2022;33:134-139. [DOI: 10.35366/107628] [Reference Citation Analysis]
27 Shalimar, Elhence A, Bansal B, Gupta H, Anand A, Singh TP, Goel A. Prevalence of Non-alcoholic Fatty Liver Disease in India: A Systematic Review and Meta-analysis. J Clin Exp Hepatol 2022;12:818-29. [PMID: 35677499 DOI: 10.1016/j.jceh.2021.11.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
28 Lee N, Heo YJ, Choi SE, Jeon JY, Han SJ, Kim DJ, Kang Y, Lee KW, Kim HJ. Hepatoprotective effects of gemigliptin and empagliflozin in a murine model of diet-induced non-alcoholic fatty liver disease. Biochem Biophys Res Commun 2021;588:154-60. [PMID: 34971904 DOI: 10.1016/j.bbrc.2021.12.065] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
29 Ramai D, Facciorusso A. Liver Cancer Reduction After Bariatric Surgery: Time to Expand Its Indication? Gastroenterology 2021;161:2063. [PMID: 33811922 DOI: 10.1053/j.gastro.2021.03.053] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
30 Márquez-Quiroga LV, Arellanes-Robledo J, Vásquez-Garzón VR, Villa-Treviño S, Muriel P. Models of nonalcoholic steatohepatitis potentiated by chemical inducers leading to hepatocellular carcinoma. Biochem Pharmacol 2022;195:114845. [PMID: 34801522 DOI: 10.1016/j.bcp.2021.114845] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
31 Yamamoto K, Honda T, Yokoyama S, Ma L, Kato A, Ito T, Ishizu Y, Kuzuya T, Nakamura M, Kawashima H, Ishigami M, Tsuji NM, Fujishiro M. Microbiome, fibrosis and tumor networks in a non-alcoholic steatohepatitis model of a choline-deficient high-fat diet using diethylnitrosamine. Dig Liver Dis 2021;53:1443-50. [PMID: 33726979 DOI: 10.1016/j.dld.2021.02.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Nakanishi N, Hashimoto Y, Okamura T, Ohbora A, Kojima T, Hamaguchi M, Fukui M. A weight regain of 1.5 kg or more and lack of exercise are associated with nonalcoholic fatty liver disease recurrence in men. Sci Rep 2021;11:19992. [PMID: 34620897 DOI: 10.1038/s41598-021-99036-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
33 Rinaldi L, Vetrano E, Rinaldi B, Galiero R, Caturano A, Salvatore T, Sasso FC. HCC and Molecular Targeting Therapies: Back to the Future. Biomedicines 2021;9:1345. [PMID: 34680462 DOI: 10.3390/biomedicines9101345] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
34 Sharma N, Biswas S, Al-Dayan N, Alhegaili AS, Sarwat M. Antioxidant Role of Kaempferol in Prevention of Hepatocellular Carcinoma. Antioxidants (Basel) 2021;10:1419. [PMID: 34573051 DOI: 10.3390/antiox10091419] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
35 Lefebvre P, Staels B. Hepatic sexual dimorphism - implications for non-alcoholic fatty liver disease. Nat Rev Endocrinol 2021;17:662-70. [PMID: 34417588 DOI: 10.1038/s41574-021-00538-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
36 Tutunchi H, Naeini F, Ebrahimi-Mameghani M, Najafipour F, Mobasseri M, Ostadrahimi A. Metabolically healthy and unhealthy obesity and the progression of liver fibrosis: A cross-sectional study. Clin Res Hepatol Gastroenterol 2021;45:101754. [PMID: 34303827 DOI: 10.1016/j.clinre.2021.101754] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
37 Safcak D, Drazilova S, Gazda J, Andrasina I, Adamcova-Selcanova S, Barila R, Mego M, Rac M, Skladany L, Zigrai M, Janicko M, Jarcuska P. Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: Clinical Patterns, Outcomes, and Prognostic Factors for Overall Survival-A Retrospective Analysis of a Slovak Cohort. J Clin Med 2021;10:3186. [PMID: 34300352 DOI: 10.3390/jcm10143186] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Matboli M, Gadallah SH, Rashed WM, Hasanin AH, Essawy N, Ghanem HM, Eissa S. mRNA-miRNA-lncRNA Regulatory Network in Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2021;22:6770. [PMID: 34202571 DOI: 10.3390/ijms22136770] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
39 Meng L, Goto M, Tanaka H, Kamikokura Y, Fujii Y, Okada Y, Furukawa H, Nishikawa Y. Decreased Portal Circulation Augments Fibrosis and Ductular Reaction in Nonalcoholic Fatty Liver Disease in Mice. Am J Pathol 2021;191:1580-91. [PMID: 34119474 DOI: 10.1016/j.ajpath.2021.06.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Gadallah SH, Eissa S, Ghanem HM, Ahmed EK, Hasanin AH, El Mahdy MM, Matboli M. Probiotic-prebiotic-synbiotic modulation of (YAP1, LATS1 and NF2 mRNAs/miR-1205/lncRNA SRD5A3-AS1) panel in NASH animal model. Biomed Pharmacother 2021;140:111781. [PMID: 34090052 DOI: 10.1016/j.biopha.2021.111781] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
41 Oyama A, Nouso K, Yoshimura K, Morimoto Y, Nakamura S, Onishi H, Takaki A, Iwadou S, Kariyama K, Kuwaki K, Yabushita K, Sakaguchi K, Toshimori J, Kobashi H, Moriya A, Ando M, Okada H; Okayama Hepatocellular Carcinoma Study Group. Randomized controlled study to examine the efficacy of hepatic arterial infusion chemotherapy with cisplatin before radiofrequency ablation for hepatocellular carcinoma. Hepatol Res 2021;51:694-701. [PMID: 33687130 DOI: 10.1111/hepr.13633] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
42 Barcena-Varela M, Lujambio A. The Endless Sources of Hepatocellular Carcinoma Heterogeneity. Cancers (Basel) 2021;13:2621. [PMID: 34073538 DOI: 10.3390/cancers13112621] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
43 Møller S, Kimer N, Kronborg T, Grandt J, Hove JD, Barløse M, Gluud LL. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Overlapping Mechanisms. Semin Liver Dis 2021;41:235-47. [PMID: 33992031 DOI: 10.1055/s-0041-1725022] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
44 Younossi ZM, Henry L. Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma. JHEP Rep 2021;3:100305. [PMID: 34189448 DOI: 10.1016/j.jhepr.2021.100305] [Cited by in Crossref: 31] [Cited by in F6Publishing: 37] [Article Influence: 15.5] [Reference Citation Analysis]
45 Tutunchi H, Naeini F, Mobasseri M, Ostadrahimi A. Triglyceride glucose (TyG) index and the progression of liver fibrosis: A cross-sectional study. Clin Nutr ESPEN 2021;44:483-7. [PMID: 34330512 DOI: 10.1016/j.clnesp.2021.04.025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
46 Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell 2021;184:2537-64. [PMID: 33989548 DOI: 10.1016/j.cell.2021.04.015] [Cited by in Crossref: 219] [Cited by in F6Publishing: 255] [Article Influence: 109.5] [Reference Citation Analysis]
47 Lam L, Fontaine H, Bourliere M, Lusivika-Nzinga C, Dorival C, Thabut D, Zoulim F, Habersetzer F, Asselah T, Duclos-Vallee JC, Bronowicki JP, Mathurin P, Decaens T, Ganne N, Guyader D, Leroy V, Rosa I, De Ledinghen V, Cales P, Causse X, Larrey D, Chazouilleres O, Gelu-Simeon M, Loustaud-Ratti V, Metivier S, Alric L, Riachi G, Gournay J, Minello A, Tran A, Geist C, Abergel A, Raffi F, D'Alteroche L, Portal I, Lapidus N, Pol S, Carrat F; ANRS/AFEF Hepather study group. Predictive factors for hepatocellular carcinoma in chronic hepatitis B using structural equation modeling: a prospective cohort study. Clin Res Hepatol Gastroenterol 2021;45:101713. [PMID: 33930591 DOI: 10.1016/j.clinre.2021.101713] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
48 Chaudhari R, Fouda S, Sainu A, Pappachan JM. Metabolic complications of hepatitis C virus infection. World J Gastroenterol 2021;27:1267-82. [PMID: 33833481 DOI: 10.3748/wjg.v27.i13.1267] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
49 Lonardo A. Renaming NAFLD to MAFLD: Could the LDE System Assist in This Transition? J Clin Med 2021;10:492. [PMID: 33572544 DOI: 10.3390/jcm10030492] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
50 Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers 2021;7:6. [PMID: 33479224 DOI: 10.1038/s41572-020-00240-3] [Cited by in Crossref: 889] [Cited by in F6Publishing: 998] [Article Influence: 444.5] [Reference Citation Analysis]
51 Moctezuma-velázquez C. Editorial comment on hepatocellular carcinoma in the noncirrhotic liver: Clinical characteristics and results in Veracruz, Mexico. Revista de Gastroenterología de México (English Edition) 2021;86:1-3. [DOI: 10.1016/j.rgmxen.2020.05.005] [Reference Citation Analysis]
52 Moctezuma-velázquez C. Comentario editorial sobre carcinoma hepatocelular en hígado no cirrótico: características clínicas y resultados en Veracruz, México. Revista de Gastroenterología de México 2021;86:1-3. [DOI: 10.1016/j.rgmx.2020.05.003] [Reference Citation Analysis]
53 Brillanti S, Alterini G. The role of gut microbiota in chronic liver diseases. The Complex Interplay Between Gut-Brain, Gut-Liver, and Liver-Brain Axes 2021. [DOI: 10.1016/b978-0-12-821927-0.00003-6] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
54 Bedi S, Davis A, Navarro V. Reducing the Risk of and Screening for Liver Cancer. Hepato-Pancreato-Biliary Malignancies 2021. [DOI: 10.1007/978-3-030-37482-2_12-1] [Reference Citation Analysis]
55 Awaad AK, Kamel MA, Mohamed MM, Helmy MH, Youssef MI, Zaki EI, Essawy MM, Hegazy MGA. The role of hepatic transcription factor cAMP response element-binding protein (CREB) during the development of experimental nonalcoholic fatty liver: a biochemical and histomorphometric study. Egypt Liver Journal 2020;10. [DOI: 10.1186/s43066-020-00046-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
56 Straś W, Małkowski P, Tronina O. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis - epidemiology, risk factors, clinical implications and treatment. Clin Exp Hepatol 2020;6:170-5. [PMID: 33145423 DOI: 10.5114/ceh.2020.99506] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
57 Tan Y, Lin XT, Luo YD, Zhang J, Fang L, Zhu YY, Yu HQ, Shuai L, Jiang Y, Zhang LD, Bie P, Xie CM. Reduced IκBα promotes hepatocellular carcinoma cell proliferation and migration via regulation of NF-κB/Erbin axis. Oncol Lett 2020;20:216. [PMID: 32963622 DOI: 10.3892/ol.2020.12079] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
58 Martínez-Chantar ML, Avila MA, Lu SC. Hepatocellular Carcinoma: Updates in Pathogenesis, Detection and Treatment. Cancers (Basel) 2020;12:E2729. [PMID: 32977536 DOI: 10.3390/cancers12102729] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
59 Tamitani M, Yamamoto T, Yamamoto N, Fujisawa K, Tanaka S, Nakamura Y, Uchinoumi H, Oda T, Okuda S, Takami T, Kobayashi S, Sakaida I, Yano M. Dantrolene prevents hepatic steatosis by reducing cytoplasmic Ca2+ level and ER stress. Biochemistry and Biophysics Reports 2020;23:100787. [DOI: 10.1016/j.bbrep.2020.100787] [Reference Citation Analysis]
60 Uchida D, Takaki A, Oyama A, Adachi T, Wada N, Onishi H, Okada H. Oxidative Stress Management in Chronic Liver Diseases and Hepatocellular Carcinoma. Nutrients 2020;12:E1576. [PMID: 32481552 DOI: 10.3390/nu12061576] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
61 Cremonese C, Schierwagen R, Uschner FE, Torres S, Tyc O, Ortiz C, Schulz M, Queck A, Kristiansen G, Bader M, Sauerbruch T, Weiskirchen R, Walther T, Trebicka J, Klein S. Short-Term Western Diet Aggravates Non-Alcoholic Fatty Liver Disease (NAFLD) With Portal Hypertension in TGR(mREN2)27 Rats. Int J Mol Sci 2020;21:E3308. [PMID: 32392802 DOI: 10.3390/ijms21093308] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
62 Majeed CN, Ahmad MI, Ahsan I, Anees MA, Maheshwari SK, Soliman EZ. Response to the Letter to the Editor. Ann Noninvasive Electrocardiol 2020;25:e12756. [PMID: 32154617 DOI: 10.1111/anec.12756] [Reference Citation Analysis]